PHILADELPHIA — The average wait time for a kidney transplant is five years and there are more than 100,000 people on the waiting list. However, there are thousands of viable hepatitis C-positive kidneys that are discarded each year solely because they’re infected. A new perspective paper written by researchers at the Perelman School of Medicine at the University of Pennsylvania and published in The New England Journal of Medicine suggests that “new antiviral therapies with cure rates exceeding 95 percent should prompt transplant-community leaders to view HCV (hepatitis C virus)-positive organs as a valuable opportunity for transplant candidates with or without pre-existing HCV infection.”
The authors, led by Peter P. Reese, MD, MSCE, an assistant professor in the Renal, Electrolyte and Hypertension Division, and David Goldberg, MD, MSCE, an assistant professor in the Gastroenterology Division at Penn, acknowledge that intentionally infecting patients with hepatitis C through transplantation will require significant oversight and consideration. However, they assert that the benefit to patients who would otherwise have had little chance of kidney transplantation far outweigh the concerns. They write that “the resulting expansion of the donor pool could save hundreds of lives each year.”
For example, the authors suggest that hepatitis C-positive kidneys should be offered to uninfected patients who have a high risk of health deterioration if they continue dialysis — including elderly patients or those with serious co-existing conditions, such as cardiovascular disease — disadvantageous blood types or other conditions that would mean many years of waiting for an appropriate hepatitis C-negative kidney to become available. In fact, they assert that “providing HCV-positive kidneys and HCV therapy to HCV-negative recipients will lead to better outcomes than dialysis.”
In order to make this work, the authors describe necessary steps of a rigorous informed consent process that outlines the risks and uncertainties, close involvement of institutional review boards, and multicenter trials to collect data. The authors also acknowledge that although the costs of transplanting hepatitis C-infected kidneys into uninfected recipients would be high, they may be offset by savings from reduced dialysis time for recipients who would otherwise wait longer for a kidney.
The other authors, who are also from Penn, include Peter L. Abt, MD, and Emily A. Blumberg, MD.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.